Viral infections and their impact on chronic renal allograft dysfunction

Transplantation

Volumn 71, Issue 11 SUPPL., 2001, Pages

  Soderberg Naucler C ^a   Emery, V C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; GRAFT SURVIVAL; HUMAN; HUMAN CYTOMEGALOVIRUS; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; VIRUS INFECTION;

ANTIVIRAL AGENTS; CHRONIC DISEASE; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MUSCLE, SMOOTH, VASCULAR; VIRUS DISEASES;

EID: 0035876690     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Infectious complications following renal transplantation
2. Viral infections in organ transplantation
3. Look-up survival tables for renal transplantation
4. Cytomegalovirus infection-an etiological factor for rejection? A prospective study in 242 renal transplant patients
5. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients
6. Cytomegalovirus is involved in vascular pathology
7. Designing studies to confirm a link between viral infection and atherosclerosis
8. Coronary artery disease after heart transplantation and its relation to cytomegalovirus
9. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis
10. Human cytomegalovirus: A viral complication in transplantation
11. Circulating human cytomegalovirus (HCMV)-infected endothelial cells in patients with an active HCMV infection
12. Ultrastructural analysis of circulating cytomegalic cells in patients with active cytomegalovirus infection: Evidence for virus production and endothelial origin
13. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
14. Impact of cytomegalovirus infection in organ transplant recipients
15. Infection in organ-transplant recipients
16. The pathogenicity of cytomegalovirus
17. Overcoming the problem of cytomegalovirus infection after organ transplantation: Calling for Heracles?
18. Viral dynamics during active cytomegalovirus infection and pathology
19. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
20. Human cytomegalovirus escape from immune detection
21. Molecular mimicry by cytomegaloviruses. Function of cytomegalovirus-encoded homologues of G protein-coupled receptors, MHC class I heavy chains and chemokines
22. Immune evasion by cytomegalovirus-survival strategies of a highly adapted opportunist
23. Human cytomegalovirus blocks interferon-g stimulated up-regulation of major histocompatibility complex class I expression and the class I antigen processing machinery
24. Human cytomegalovirus inhibits IFN-a-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-a signal transduction
25. Cytomegaloviruses use multiple mechanisms to elude the host immune response
26. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chain
27. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product
28. Viral inhibition of interferon signal transduction
29. Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells
30. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
31. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells
32. Cytomegalovirus evasion of natural killer cell responses
33. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40
34. Chemokine sequestration by viral chemoreceptors as a novel escape strategy: Withdrawal of chemokines from the environment of cytomegalovirus-infected cells
35. Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: An in vitro model
36. Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemkines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration
37. Tissue macrophages are infected by human cytomegalovirus in vivo
38. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers
39. Human cytomegalovirus productively infects primary differentiated macrophages
40. Cytomegalovirus infects human lymphocytes and monocytes: Virus expression is restricted to immediate-early gene products
41. Interferon-g and tumor necrosis factor-a specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines
42. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis
43. Cachexia and tumor necrosis factor-α in cytomegalovirus infection
44. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation
45. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor
46. Tumor necrosis factor a stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells
47. CMV infection, class II antigen expression, and human kidney allograft rejection
48. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation
49. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation
50. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent cofactors in pathogenesis of vanishing bile-duct syndrome after liver transplantation
51. Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: Effect of acute rejection
52. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients
53. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection
54. The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients
55. Circulating ICAM-1: Novel parameter of renal graft rejection
56. Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression
57. Cytomegalovirus directly enhances MHC class I and intercellular adhesion molecule-1 expression on cultured proximal tubular epithelial cells
58. Rejection after kidney transplantation: New concepts, new therapeutic options
59. Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus-infected endothelial cells: Role of MHC class I antigens
60. Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis
61. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy
62. Cytomegalovirus nucleic acids in allografted hearts
63. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat
64. Cytomegalovirus infection-associated generalized immune activation in heart allograft recipients: A study of cellular events in peripheral blood and endomyocardial biopsy specimens
65. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis
66. The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts
67. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts
68. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF b-receptor
69. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration
70. Decreased lesion formation in CCR1 mice reveals a role for chemokines in the initiation of atherosclerosis
71. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation
72. Human cytomegalovirus: Challenges opportunities and new drug development
73. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro
74. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation